Amedeo Smart

Free Medical Literature Service

 

Amedeo

Dyslipidemia
  Free Subscription

Articles published in
Curr Opin Lipidol
    October 2025
  1. KRAUTTER F, Fisher EA
    Cycling of metabolic states and metabolites as drivers of atherosclerosis.
    Curr Opin Lipidol. 2025;36:251-257.
    >> Share

    June 2025
  2. PRAKASH Y, Bhatt DL, Malick WA
    Emerging agents targeting triglycerides.
    Curr Opin Lipidol. 2025;36:119-129.
    >> Share

    April 2025
  3. TADA H, Nohara A, Kawashiri MA, Takamura M, et al
    Impact of Achilles tendon on diagnosis and phenotypes of familial hypercholesterolemia.
    Curr Opin Lipidol. 2025 Apr 14. doi: 10.1097/MOL.0000000000000992.
    >> Share

  4. HEGELE RA
    What is the phenotype of heterozygous lipoprotein lipase deficiency?
    Curr Opin Lipidol. 2025;36:96-103.
    >> Share

  5. ISON HE, Helm B, Kringlen G, Crawford P, et al
    Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients.
    Curr Opin Lipidol. 2025;36:49-54.
    >> Share

    March 2025
  6. ALNOURI F, Raal FJ
    Familial hypercholesterolemia in pregnancy.
    Curr Opin Lipidol. 2025 Mar 7. doi: 10.1097/MOL.0000000000000980.
    >> Share

    December 2024
  7. TAMEHRI ZADEH SS, Pang J, Chan DC, Watts GF, et al
    A contemporary snapshot of familial hypercholesterolemia registries.
    Curr Opin Lipidol. 2024;35:297-302.
    >> Share

    November 2024
  8. BIRKENHEAD K, Sullivan D, Watts GF, Sarkies MN, et al
    Implementation science and genetic testing for familial hypercholesterolemia.
    Curr Opin Lipidol. 2024 Nov 26. doi: 10.1097/MOL.0000000000000967.
    >> Share

  9. PAQUETTE M, Guay SP, Baass A
    Genetic determinants of pancreatitis risk in hypertriglyceridemia.
    Curr Opin Lipidol. 2024 Nov 11. doi: 10.1097/MOL.0000000000000962.
    >> Share

    September 2024
  10. RAMASWAMI U, Priestley-Barnham L, Humphries SE
    Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families.
    Curr Opin Lipidol. 2024 Sep 27. doi: 10.1097/MOL.0000000000000952.
    >> Share

    August 2024
  11. FOSTER C, Gagnon CA, Ashraf AP
    Altered lipid metabolism and the development of metabolic-associated fatty liver disease.
    Curr Opin Lipidol. 2024;35:200-207.
    >> Share

    June 2024
  12. BASHIR B, Ferdousi M, Durrington PN, Soran H, et al
    Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia.
    Curr Opin Lipidol. 2024 Jun 7. doi: 10.1097/MOL.0000000000000939.
    >> Share

  13. MULDER JWCM, Kusters DM, Roeters van Lennep JE, Hutten BA, et al
    Lipid metabolism during pregnancy: consequences for mother and child.
    Curr Opin Lipidol. 2024;35:133-140.
    >> Share

    April 2024
  14. BRUNHAM LR
    Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?
    Curr Opin Lipidol. 2024 Apr 22. doi: 10.1097/MOL.0000000000000938.
    >> Share

  15. CIVEIRA F, Martin C, Cenarro A
    APOE and familial hypercholesterolemia.
    Curr Opin Lipidol. 2024 Apr 17. doi: 10.1097/MOL.0000000000000937.
    >> Share

  16. RASMUSSEN KL, Frikke-Schmidt R
    The current state of apolipoprotein E in dyslipidemia.
    Curr Opin Lipidol. 2024;35:78-84.
    >> Share

  17. WEN Y, Chen YQ, Konrad RJ
    Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism.
    Curr Opin Lipidol. 2024;35:58-65.
    >> Share

    February 2024
  18. CHAN DC, Watts GF
    ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
    Curr Opin Lipidol. 2024 Feb 20. doi: 10.1097/MOL.0000000000000920.
    >> Share

  19. VAN DEN BOSCH SE, Hutten BA, Corpeleijn WE, Kusters DM, et al
    Familial hypercholesterolemia in children and the importance of early treatment.
    Curr Opin Lipidol. 2024 Feb 15. doi: 10.1097/MOL.0000000000000926.
    >> Share

  20. PAPONJA K, Pecin I, Reiner Z, Banach M, et al
    Bempedoic acid: new evidence and recommendations on use.
    Curr Opin Lipidol. 2024;35:41-50.
    >> Share

  21. ZHANG Y, de Ferranti SD, Moran AE
    Genetic testing for familial hypercholesterolemia.
    Curr Opin Lipidol. 2024 Feb 1. doi: 10.1097/MOL.0000000000000925.
    >> Share

    December 2023
  22. PERERA SD, Hegele RA
    Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
    Curr Opin Lipidol. 2023 Dec 21. doi: 10.1097/MOL.0000000000000916.
    >> Share

  23. ROMERO-JIMENEZ MJ, Mansilla-Rodriguez ME, Gutierrez-Cortizo EN
    Predictors of cardiovascular risk in familial hypercholesterolemia.
    Curr Opin Lipidol. 2023;34:272-277.
    >> Share

  24. GILLARD BK, Rosales C, Gotto AM Jr, Pownall HJ, et al
    The pathophysiology of excess plasma-free cholesterol.
    Curr Opin Lipidol. 2023;34:278-286.
    >> Share

  25. KARALIS DG
    Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:252-258.
    >> Share

    November 2023
  26. ROY G, Drouin-Chartier JP
    Cardiovascular disease prevention in heterozygous familial hypercholesterolemia: how important is a healthy diet in the era of long-lasting cholesterol-lowering drug therapies?
    Curr Opin Lipidol. 2023 Nov 2. doi: 10.1097/MOL.0000000000000908.
    >> Share

    October 2023
  27. CHATTOPADHYAY A, Reddy ST, Fogelman AM
    The multiple roles of lysophosphatidic acid in vascular disease and atherosclerosis.
    Curr Opin Lipidol. 2023;34:196-200.
    >> Share

    August 2023
  28. CHOUDHARI P, Patni N
    Updates in the management of pediatric dyslipidemia.
    Curr Opin Lipidol. 2023;34:156-161.
    >> Share

    June 2023
  29. GANDA OP
    Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:105-113.
    >> Share

  30. WADSTROM BN, Pedersen KM, Wulff AB, Nordestgaard BG, et al
    Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:96-104.
    >> Share

    April 2023
  31. CLARKE SL
    Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?
    Curr Opin Lipidol. 2023;34:52-58.
    >> Share

  32. HEGELE RA
    DNA testing in dyslipidemia: attitudes and complexities.
    Curr Opin Lipidol. 2023;34:33-34.
    >> Share

    March 2023
  33. VUORIO A, Raal F, Kovanen PT
    Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19.
    Curr Opin Lipidol. 2023 Mar 10. doi: 10.1097/MOL.0000000000000876.
    >> Share

    February 2023
  34. HANG SMT, Hegele RA, Berberich AJ
    Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia.
    Curr Opin Lipidol. 2023 Feb 2. doi: 10.1097/MOL.0000000000000866.
    >> Share

    January 2023
  35. REIJMAN MD, Defesche JC, Wiegman A
    Genotype-phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2023 Jan 18. doi: 10.1097/MOL.0000000000000863.
    >> Share

    December 2022
  36. DRON JS
    The clinical utility of polygenic risk scores for combined hyperlipidemia.
    Curr Opin Lipidol. 2022 Dec 28. doi: 10.1097/MOL.0000000000000865.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016